Table 5: Key eligibility criteria for reimbursement of paritaprevir-ritonavir-ombitasvir plus dasabuvir (with or without ribavirin) for treatment of hepatitis C virus infection, by jurisdiction.
Jurisdiction | Restriction | ||||
---|---|---|---|---|---|
Minimum fibrosis stage required | Substance use | HIV coinfection | Prescriber | Decompensated cirrhosis | |
Province/territory | |||||
British Columbia | F2 | None listed* | Eligible | General practitioner | None listed |
Alberta | F2 | None listed | Eligible | General practitioner | Ineligible |
Saskatchewan | F2 | None listed† | Eligible | General practitioner | Ineligible |
Manitoba | F2 | None listed | Eligible | Specialist | Ineligible |
Ontario | F2 | None listed | Eligible | General practitioner | Ineligible |
Quebec | F3‡ | None listed | Eligible§ | General practitioner | Ineligible |
New Brunswick | F2 | None listed | Eligible | General practitioner | Ineligible |
Nova Scotia | F2 | None listed | Eligible | Specialist | Ineligible |
Prince Edward Island | No restrictions | None listed¶ | Eligible** | General practitioner | None listed |
Newfoundland and Labrador | F2 | None listed | Eligible | General practitioner | Ineligible |
Yukon | F2 | None listed | Eligible | Specialist | Ineligible |
Northwest Territories | F2 | None listed | None listed | None listed | None listed |
Nunavut | F2 | None listed | None listed | None listed | None listed |
Federal | |||||
Non-Insured Health Benefits Program | F2 | None listed | None listed | None listed | None listed |
Correctional Service Canada | F2†† | None listed | None listed | None listed | None listed |
*No specific criteria, but exclusion criteria stated: "Patients who are at high risk for non-compliance."
†However, prescriber could indicate that directly observed therapy was recommended; also, the patient consented (via signature) to understanding treatment adherence.
‡In year 1 (2015/16), only those with stage F3 or F4 fibrosis received reimbursement.
§Treated in year 1 if stage F3 or F4 fibrosis.
¶There were restrictions (e.g., active injection drug use) left to physician's discretion.
**Must be treated by a specialist off-island.
††Treatment prioritized to patients with stage F3 or F4 fibrosis; treatment for those with stage F0, F1 or F2 fibrosis was reviewed on a case-by-case basis.